KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Current Deferred Revenue (2023)

Biocryst Pharmaceuticals' Current Deferred Revenue history spans 7 years, with the latest figure at $522000.0 for Q3 2023.

  • For Q3 2023, Current Deferred Revenue changed N/A year-over-year to $522000.0; the TTM value through Sep 2023 reached $522000.0, changed N/A, while the annual FY2014 figure was $5.6 million, 280.52% up from the prior year.
  • Current Deferred Revenue reached $522000.0 in Q3 2023 per BCRX's latest filing, down from $1.8 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.8 million in Q2 2023 to a low of $522000.0 in Q3 2023.